Data gathered: November 22
AI Stock Analysis - Cybin (CYBN)
Analysis generated March 20, 2024. Powered by Chat GPT.
Cybin is a company operating in the biotechnology field, focusing on the development of psychedelic and nutraceutical products to mitigate psychiatric and neurological conditions. The firm is at the forefront of using psychedelic compounds to create therapies for mental health disorders. Leveraging innovative drug delivery systems, Cybin aims to improve the bioavailability and efficacy of their medicinal compounds, potentially offering a novel approach to treatment in a market eager for alternatives to traditional pharmaceuticals. Due to the experimental nature of its product pipeline, Cybin is positioned as a speculative investment with long-term growth potential, appealing to investors interested in cutting-edge health science and the future of mental health treatment.
Stock Alerts - Cybin (CYBN)
 |
Cybin | November 21 Price is down by -5.1% in the last 24h. |
|
Cybin | November 19 Price is up by 6.9% in the last 24h. |
|
Cybin | November 18 Price is up by 11.6% in the last 24h. |
|
Cybin | November 15 Price is up by 13.6% in the last 24h. |
Alternative Data for Cybin
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 16,000 | Sign up | Sign up | Sign up |
| Google Trends | 50 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 35 | Sign up | Sign up | Sign up |
| Facebook Followers | 11,752 | Sign up | Sign up | Sign up |
| Instagram Followers | 15,658 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 22 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,073 | Sign up | Sign up | Sign up |
| Twitter Followers | 9,062 | Sign up | Sign up | Sign up |
| Twitter Mentions | 9 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 68 | Sign up | Sign up | Sign up |
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
| Price | $10.16 |
| Target Price | Sign up |
| Volume | 962,670 |
| Market Cap | $220M |
| Year Range | $7.6 - $17.6 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive DisorderNovember 18 - Financial Post |
|
 |
Cybin reports sustained depression treatment effectsNovember 18 - Investing.com |
 |
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024November 13 - Yahoo |
 |
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial ResultsNovember 12 - Yahoo |
 |
Cybin Inc: Another High-Risk Psychedelics PlayNovember 2 - SeekingAlpha |
 |
Cybin to Participate at the 2024 Milken Institute Future of Health SummitOctober 30 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 0 | 140,000 | -140,000 | -15M | -20M | -0.020 |
| Q1 '24 | 0 | 140,000 | -140,000 | -21M | -29M | -0.020 |
| Q4 '23 | 0 | 140,000 | -140,000 | -21M | -25M | -0.090 |
| Q3 '23 | 0 | 140,000 | -140,000 | -30M | -27M | -0.050 |
| Q2 '23 | 0 | 69,000 | -69,000 | -12M | -14M | -0.070 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Cybin (CYBN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Cybin?
The Market Cap of Cybin is $220M.
What is the current stock price of Cybin?
Currently, the price of one share of Cybin stock is $10.16.
How can I analyze the CYBN stock price chart for investment decisions?
The CYBN stock price chart above provides a comprehensive visual representation of Cybin's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cybin shares. Our platform offers an up-to-date CYBN stock price chart, along with technical data analysis and alternative data insights.
Does CYBN offer dividends to its shareholders?
As of our latest update, Cybin (CYBN) does not offer dividends to its shareholders. Investors interested in Cybin should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cybin?
Some of the similar stocks of Cybin are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.